Public health authorities outline who needs which vaccines, organized by age and other key variables—important information ...

The Food and Drug Administration on Monday approved Merck’s new pneumococcal vaccine for adults 18 and older. The vaccine, which will be sold under the name Capvaxive, is designed to protect against ...

This review was funded by The Permanente Medical Group. G Thomas Ray has received research grants from Wyeth Pharmaceuticals. The author has no other relevant affiliations or financial involvement ...

U.S. health officials on Wednesday recommended that people 50 and older get a shot against bacteria that can cause pneumonia and other dangerous illnesses. The recommendation was made by a scientific ...

Background.In 2013, Burkina Faso introduced 13-valent pneumococcal conjugate vaccine (PCV13) into the routine childhood immunization program, to be administered to children at 8, 12, and 16 weeks of ...

Apr. 9—(StatePoint) Pneumococcal pneumonia is a potentially serious bacterial lung disease that can disrupt your life for weeks and even land you in the hospital. Medical experts want you to know that ...

The FDA approved a 21-valent pneumococcal conjugate vaccine (Capvaxive) for preventing invasive pneumococcal disease and pneumococcal pneumonia in adults, Merck announced on Monday. Specifically ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from STRIDE-3, a Phase 3 trial evaluating V116, the company’s ...

Pneumococcal disease poses a severe risk to Indian adults, particularly those with chronic health issues. Despite effective ...